Abstract:Abstract The ETS family of transcription factors is comprised of 28 members that all share a common C- terminal DNA-binding domain. ETS play essential roles in developmental processes, such as stem cell maintenance, blood vessel formation, and cellular fate. While absent in the normal prostate, four members of the ETS family become expressed in prostate tumors: ETV1, ETV4, ETV5 and ERG. Our lab has previously classified these proteins as oncogenic ETS for their ability to promote cellular migration in normal prostate epithelial RWPE1 cells. Transcription factors may need to interact with additional proteins to serve oncogenic roles. My research explores the interactions between 1) ETV1 and EWS, as well as 2) ERG and p53. Our lab has established that ETV1, ETV4 and ETV5 form essential interactions with EWS, a transcriptional coactivator that promotes ETS activity. In prostate tumors, chromosomal rearrangements result in the N-terminal truncations of ETV1, ETV4 and ETV5. I hypothesize that the EWS interaction domain is retained and that these truncated ETVs will remain oncogenic. Pulldown assays using purified full-length and truncated ETV1 suggests EWS interacts with both N-terminal and C-terminal portions ETV1. I am attempting to express truncated ETV1, ETV4 and ETV5 in RWPE1 cells. Upon stable expression, I will evaluate their interactions with EWS and their ability to promote migration in vitro. To identify putative proteins that bridge EWS to ETV1, immunoprecipitation mass spectrometry will be used. Mutations in p53, a tumor suppressor protein, promote oncogenesis and occur in nearly half of all cancer cases. We hypothesize that mutant p53 interacts with ETS to promote its recruitment to new genomic sites. Previous studies demonstrate that mutant p53 binds ETS2 at a higher affinity than wildtype p53 and we have expanded this list of interacting ETS to include ERG. We seek to explore whether ERG and mutant p53 cooperate to promote oncogenic phenotypes. I successfully cloned wildtype p53, mutant p53 (R248W) and double-mutant p53 (R248W, T81A) into a retroviral backbone. I then transduced RWPE1-Vector and RWPE1-ERG expressing cells to express these constructs. Although additional replicates are needed, it appears that mutant p53 promotes colony formation in both cell types relative to wildtype p53. I plan to validate these observations and generate an appropriate negative control cell line before extending into a mouse model. Through the continuation of this work, I will provide critical insight into the molecular mechanisms by which a subset of ETS factors achieve oncogenic function. We address the contributions of DNA-binding specificity and coactivator interactions in promoting the phenotypes associated with prostate cancer. Citation Format: Kaitlyn M. Mills, Nicholas Downing, Stephanie Metcalf, Peter Hollenhorst. Bridging the gap: Exploring the roles of ETS- coactivator interactions in promoting prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3035.

The CIC-ERF co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression

E2F1 Renders Prostate Cancer Cell Resistant to ICAM-1 Mediated Antitumor Immunity by NF-κB Modulation.

ETS factors in prostate cancer

Re-Evaluate Fusion Genes in Prostate Cancer

Abstract 3035: Bridging the gap: Exploring the roles of ETS- coactivator interactions in promoting prostate cancer

The Progress of TMPRSS2-ETS Gene Fusions and Their Mechanism in Prostate Cancer

Oncogenic ERG Represses PI3K Signaling Through Downregulation of IRS2.

Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness

Abstract 3033: Oncogenic ETS transcription factors avoid repression by EZH2 and FOXO1 in prostate cancer and Ewing sarcoma

Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor.

ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer

Prostate cancer subtyping and differential methylation analysis based on the ETS family of transcription factors fusion genes

Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion

The Capicua C1 Domain is Required for Full Activity of the CIC::DUX4 Fusion Oncoprotein

Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer

Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG

Transcription factor ETS1‑mediated ECT2 expression promotes the malignant behavior of prostate cancer cells

Concurrent Nuclear Erg and Myc Protein Overexpression Defines A Subset of Locally Advanced Prostate Cancer: Potential Opportunities for Synergistic Targeted Therapeutics

TMPRSS2-ERG Promotes the Initiation of Prostate Cancer by Suppressing Oncogene-Induced Senescence

Polycomb-independent Activity of EZH2 in Castration Resistant Prostate Cancer

Prevalence of ETS Gene Fusion in Prostate Cancer and Its Correlation with Patients' Clinicopathologic Index